Why this ad?
Skip navigation

no spam, unsubscribe anytime.
Skip navigation

Herceptin breast cancer drug shows promise

The Herceptin drug, produced by La Roche, is showing promise of decreasing cancer recurrence, according to a new study published in The Lancet Oncology.

The study looked at 5,000 women who had been diagnosed with breast cancer between 2001 and 2005, with results indicating a 24 percent less chance of cancer return in those who took Herceptin, also known as trastuzumab, reported U.S. News.

According to The Telegraph, a British woman named Ann Marie Rogers sued and won a case to receive Herceptin in 2006.

Adriana Jenkins, a famous breast cancer awareness advocate who recently passed away, wrote a letter to Forbes in February urging personalized medicine, the method through which she received Herceptin.

Jenkins credited Herceptin for lengthening her life post-diagnosis by at least nine years, according to Forbes.

Herceptin works by suppressing the HER2/neu cancer-causing protein, according to U.S. News, and researchers are now looking into the long-term use of Herceptin.

"We were inclined to consider the possibility that long-term exposure to trastuzumab deserved a proper test and might be useful," Dr. Luca Gianni, of Milan's Fondazione San Raffaele, told the news source following the new studies. 
Why this ad? Why this ad? Why this ad? God Has This One Pink Ribbon Necklace
Share this page and help fund mammograms: